The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

The four trials also assessed efficacy of the ICS/LABA products. Based on a review of four clinical safety trials, the Food and Drug Administration (FDA) has concluded that medications that contain ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Current drug treatments have been incorporated into clinical practice guidelines, such as the NAEPP EPR-3 for asthma [101] and GOLD treatment guidelines for COPD, [102] both of which recognize the ...

Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds. Adding long-acting muscarinic antagonists ...

Photomicrograph of salivary gland of a person with Sjögren’s syndrome, characterized by the abnormal migration of of lymphocytes T and B. Here the lymphocytes T and B appear in mauve. Investigators ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

Among patients with mild asthma, as-needed use of a fixed-dose inhaler combining budesonide and formoterol (Symbicort) proved effective for preventing exacerbations and loss of lung function, but the ...

Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential of developmental combination treatment, Relovair, in COPD and asthma LONDON and SOUTH SAN ...